PetIQ, Inc. (PETQ)
USD 30.98
(-0.03%)
USD 30.98
(-0.03%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.1 Billion USD | 19.58% |
| 2022 | 921.51 Million USD | -1.18% |
| 2021 | 932.52 Million USD | 19.55% |
| 2020 | 780.05 Million USD | 9.95% |
| 2019 | 709.43 Million USD | 34.21% |
| 2018 | 528.61 Million USD | 98.22% |
| 2017 | 266.68 Million USD | 33.24% |
| 2016 | 200.16 Million USD | -2.69% |
| 2015 | 205.68 Million USD | 27.37% |
| 2014 | 161.49 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 308.44 Million USD | 40.25% |
| 2024 Q2 | 328.94 Million USD | 6.65% |
| 2023 Q3 | 277.01 Million USD | -11.93% |
| 2023 Q4 | 219.92 Million USD | -20.61% |
| 2023 FY | 1.1 Billion USD | 19.58% |
| 2023 Q2 | 314.54 Million USD | 8.29% |
| 2023 Q1 | 290.47 Million USD | 57.8% |
| 2022 Q3 | 209.72 Million USD | -16.78% |
| 2022 FY | 921.51 Million USD | -1.18% |
| 2022 Q1 | 275.69 Million USD | 40.21% |
| 2022 Q4 | 184.07 Million USD | -12.23% |
| 2022 Q2 | 252.01 Million USD | -8.59% |
| 2021 Q1 | 254.34 Million USD | 54.89% |
| 2021 Q2 | 271.01 Million USD | 6.55% |
| 2021 Q3 | 210.53 Million USD | -22.32% |
| 2021 Q4 | 196.63 Million USD | -6.6% |
| 2021 FY | 932.52 Million USD | 19.55% |
| 2020 Q3 | 162.08 Million USD | -39.29% |
| 2020 Q2 | 266.98 Million USD | 42.94% |
| 2020 Q1 | 186.77 Million USD | 21.02% |
| 2020 FY | 780.05 Million USD | 9.95% |
| 2020 Q4 | 164.2 Million USD | 1.31% |
| 2019 Q4 | 154.33 Million USD | -17.03% |
| 2019 FY | 709.43 Million USD | 34.21% |
| 2019 Q3 | 186.02 Million USD | -15.69% |
| 2019 Q2 | 220.63 Million USD | 48.64% |
| 2019 Q1 | 148.43 Million USD | 33.7% |
| 2018 FY | 528.61 Million USD | 98.22% |
| 2018 Q1 | 115.06 Million USD | 121.6% |
| 2018 Q2 | 171.14 Million USD | 48.73% |
| 2018 Q3 | 131.38 Million USD | -23.23% |
| 2018 Q4 | 111.02 Million USD | -15.5% |
| 2017 Q4 | 51.92 Million USD | -14.25% |
| 2017 Q1 | 67.02 Million USD | 49.24% |
| 2017 FY | 266.68 Million USD | 33.24% |
| 2017 Q2 | 87.17 Million USD | 30.06% |
| 2017 Q3 | 60.55 Million USD | -30.54% |
| 2016 Q1 | 52.29 Million USD | 0.0% |
| 2016 Q4 | 44.91 Million USD | 7.78% |
| 2016 Q3 | 41.67 Million USD | -32.0% |
| 2016 Q2 | 61.28 Million USD | 17.17% |
| 2016 FY | 200.16 Million USD | -2.69% |
| 2015 Q1 | 55.57 Million USD | 0.0% |
| 2015 FY | 205.68 Million USD | 27.37% |
| 2014 FY | 161.49 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 116.33 Million USD | -847.241% |
| Theratechnologies Inc. | 81.76 Million USD | -1247.736% |
| Safety Shot Inc | 202.67 Thousand USD | -543622.801% |
| Cosmos Health Inc. | 53.37 Million USD | -1964.495% |
| Cronos Group Inc. | 88.84 Million USD | -1140.378% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | -148.899% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 433.14 Million USD | -154.413% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -3310.728% |
| ProPhase Labs, Inc. | 44.38 Million USD | -2382.793% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -8553.027% |
| Dynavax Technologies Corporation | 232.28 Million USD | -374.403% |
| Radius Health, Inc. | 2.88 Billion USD | 61.767% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -57041.027% |
| Alvotech | 91.43 Million USD | -1105.2% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -4473.83% |
| Alpha Teknova, Inc. | 36.68 Million USD | -2903.934% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | -137.303% |
| SCYNEXIS, Inc. | 140.14 Million USD | -686.324% |
| Harrow Health, Inc. | 130.19 Million USD | -746.407% |
| Biofrontera Inc. | 34.07 Million USD | -3134.314% |
| DURECT Corporation | 8.54 Million USD | -12791.472% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -81.387% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | -126.361% |
| OptiNose, Inc. | 70.98 Million USD | -1452.345% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -16818.989% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -2078.524% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -2686.076% |
| SIGA Technologies, Inc. | 139.91 Million USD | -687.582% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -759.157% |
| Shineco, Inc. | 9.8 Million USD | -11142.391% |
| Phibro Animal Health Corporation | 1.01 Billion USD | -8.282% |
| Procaps Group S.A. | 409.92 Million USD | -168.824% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -84536.175% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Viatris Inc. | 15.42 Billion USD | 92.857% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -4473.83% |
| Rockwell Medical, Inc. | 83.61 Million USD | -1217.948% |
| Incannex Healthcare Limited | 12 Thousand USD | -9182925.0% |
| Aytu BioPharma, Inc. | 81 Million USD | -1260.415% |
| Tilray Brands, Inc. | 788.94 Million USD | -39.676% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | -94.43% |
| Silver Spike Investment Corp. | 11.72 Million USD | -9300.704% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 41.605% |
| Journey Medical Corporation | 79.18 Million USD | -1291.701% |
| Alimera Sciences, Inc. | 80.75 Million USD | -1264.592% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -18826.307% |
| Assertio Holdings, Inc. | 152.06 Million USD | -624.647% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Embecta Corp. | 1.12 Billion USD | 1.681% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -102274.385% |
| Procaps Group, S.A. | 409.92 Million USD | -168.824% |
| PainReform Ltd. | - USD | -Infinity% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -3840.79% |
| Hempacco Co., Inc. | 4.04 Million USD | -27138.306% |
| Talphera, Inc. | 651 Thousand USD | -169172.35% |
| Pacira BioSciences, Inc. | 674.97 Million USD | -63.259% |
| Alvotech | 91.43 Million USD | -1105.2% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 15.0% |
| Kamada Ltd. | 144.75 Million USD | -661.241% |
| Indivior PLC | 1.09 Billion USD | -0.82% |
| Currenc Group, Inc. | 53.25 Million USD | -1969.206% |
| Evoke Pharma, Inc. | 5.18 Million USD | -21170.83% |
| Flora Growth Corp. | 76.07 Million USD | -1348.598% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -102274.385% |
| Evolus, Inc. | 202.08 Million USD | -445.297% |
| HUTCHMED (China) Limited | 837.99 Million USD | -31.499% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | -71.007% |
| Akanda Corp. | 2.16 Million USD | -50915.577% |